With over 1.39 million Trillium Therapeutics Inc. (TRIL) shares trading Monday and a closing price of $8.60 on the day, the dollar volume was approximately $11.94 million. The shares have shown a positive weekly performance of 28.94% and its price on 07/20/20 gained nearly 5.91%. Currently, there are 83.44M common shares owned by the public and among those 59.89M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for TRIL have a consensus price objective of $11.25. The analysts have set the share’s price value over the next 12 months at a high of $15.00 and a low of $8.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Trillium Therapeutics Inc. stock is 1.50 for the next 12 months. The average price target is 21.96% above its last price level and an upside to the estimated low will see the stock lose -7.5% over that period. But an upside of 42.67% will see the stock hit the forecast high price target while mean target price for the stock is $11.00.
The top 3 mutual fund holders in Trillium Therapeutics Inc. are HBM Healthcare Investments, FTIF SICAV – Biotechnology Discov, and Franklin Biotechnology Discovery. HBM Healthcare Investments owns 0.99 million shares of the company’s stock, all valued at over $8.04 million. The company bought an additional 0.99 million shares recently to bring their total holdings to about 1.19% of the shares outstanding. Franklin Biotechnology Discovery now owns shares totaling to 0.77% of the shares outstanding.
Shares of Trillium Therapeutics Inc. (NASDAQ: TRIL) opened at $8.20, up $0.08 from a prior closing price of $8.12. However, the script later closed the day at $8.60, up 5.91%. The company’s stock has a 5-day price change of 28.94% and 97.25% over the past three months. TRIL shares are trading 734.95% year to date (YTD), with the 12-month market performance up to 2348.75% higher. It has a 12-month low price of $0.24 and touched a high of $9.66 over the same period. Currently, 1.39 million shares have been traded, compared to an average intraday trading volume of 1.96 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.60%, 16.97%, and 132.93% respectively.
Institutional ownership of Trillium Therapeutics Inc. (NASDAQ: TRIL) shares accounts for 32.72% of the company’s 83.44M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $717.55M. The earnings-per-share (ttm) stands at -$2.78. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.06% over the week and 9.00% over the month.
Analysts forecast that Trillium Therapeutics Inc. (TRIL) will achieve an EPS of -$0.9 for the current quarter, -$0.76 for the next quarter and -$2.92 for 2018. The lowest estimate earnings-per-share for the quarter is -$1.19 while analysts give the company a high EPS estimate of -$0.73. Comparatively, EPS for the current quarter was -$0.91 a year ago. Earnings per share for the fiscal year are expected to decrease by -26.90%, and 28.10% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Trillium Therapeutics Inc. (TRIL) as a “Strong Buy” at a consensus score of 1.50. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 1 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the TRIL, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on June 19, 2020, with the firm’s price target at. JMP Securities coverage for the Trillium Therapeutics Inc. (TRIL) stock in a research note released on May 26, 2020 offered a Mkt Outperform rating with a price target of $10. Leerink Partners was of a view on April 13, 2018 that the stock is Mkt Perform, while H.C. Wainwright gave the stock Buy rating on July 17, 2017, issuing a price target of $7. Ladenburg Thalmann on their part issued Buy rating on August 03, 2016.